146 related articles for article (PubMed ID: 32408326)
21. BRCA-deficient and triple negative breast cancers: is olaparib effective in both subtypes?
Sahin I; Ararat E; Altundag K
J BUON; 2011; 16(1):184-5. PubMed ID: 21674877
[No Abstract] [Full Text] [Related]
22. [Adjuvant olaparib - High risk early breast cancer with BRCA1 or BRCA2 germline mutation].
Bonneau M; Bellesoeur A
Bull Cancer; 2023 Nov; 110(11):1092-1093. PubMed ID: 37716861
[No Abstract] [Full Text] [Related]
23. Olaparib tablets for the treatment of germ line BRCA-mutated metastatic breast cancer.
Le D; Gelmon KA
Expert Rev Clin Pharmacol; 2018 Sep; 11(9):833-839. PubMed ID: 30118334
[TBL] [Abstract][Full Text] [Related]
24. [A Case of Metastatic Recurrent Breast Cancer Successfully with Olaparib in Late Line Therapy].
Soyama M; Kunihisa T; Shimada N; Suzuki H; Ookawa Y; Okamoto A; Yamamoto M; Miki M; Mizumoto S; Baba M; Tanino H
Gan To Kagaku Ryoho; 2021 Sep; 48(9):1153-1155. PubMed ID: 34521794
[TBL] [Abstract][Full Text] [Related]
25. BRCA2 Reversion Mutation Associated With Acquired Resistance to Olaparib in Estrogen Receptor-positive Breast Cancer Detected by Genomic Profiling of Tissue and Liquid Biopsy.
Gornstein EL; Sandefur S; Chung JH; Gay LM; Holmes O; Erlich RL; Soman S; Martin LK; Rose AV; Stephens PJ; Ross JS; Miller VA; Ali SM; Blau S
Clin Breast Cancer; 2018 Apr; 18(2):184-188. PubMed ID: 29325860
[No Abstract] [Full Text] [Related]
26. A Phase II study of olaparib in breast cancer patients: biological evaluation from a 'window of opportunity' trial.
Roviello G; Milani M; Gobbi A; Dester M; Cappelletti MR; Allevi G; Aguggini S; Ravelli A; Gussago F; Cocconi A; Zanotti L; Senti C; Strina C; Bottini A; Generali D
Future Oncol; 2016 Oct; 12(19):2189-93. PubMed ID: 27324108
[TBL] [Abstract][Full Text] [Related]
27. Is olaparib cost effective in metastatic castration-resistant prostate cancer patients with at least one favorable gene mutation in
Li Y; Lin S; Zhong L; Luo S; Huang X; Huang X; Dong L; Xu X; Weng X
Pharmacogenomics; 2021 Aug; 22(13):809-819. PubMed ID: 34517749
[No Abstract] [Full Text] [Related]
28. Olaparib shows promise in multiple tumor types.
Cancer Discov; 2013 Jul; 3(7):OF5. PubMed ID: 23847380
[TBL] [Abstract][Full Text] [Related]
29. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial.
Audeh MW; Carmichael J; Penson RT; Friedlander M; Powell B; Bell-McGuinn KM; Scott C; Weitzel JN; Oaknin A; Loman N; Lu K; Schmutzler RK; Matulonis U; Wickens M; Tutt A
Lancet; 2010 Jul; 376(9737):245-51. PubMed ID: 20609468
[TBL] [Abstract][Full Text] [Related]
30. Olaparib as maintenance therapy in patients with BRCA 1-2 mutated recurrent platinum sensitive ovarian cancer: Real world data and post progression outcome.
Cecere SC; Giannone G; Salutari V; Arenare L; Lorusso D; Ronzino G; Lauria R; Cormio G; Carella C; Scollo P; Ghizzoni V; Raspagliesi F; Di Napoli M; Mazzoni E; Marchetti C; Bergamini A; Orditura M; Valabrega G; Scambia G; Maltese G; De Matteis E; Cardalesi C; Loizzi V; Boccia S; Naglieri E; Scandurra G; Pignata S
Gynecol Oncol; 2020 Jan; 156(1):38-44. PubMed ID: 31699415
[TBL] [Abstract][Full Text] [Related]
31. Olaparib: first global approval.
Deeks ED
Drugs; 2015 Feb; 75(2):231-40. PubMed ID: 25616434
[TBL] [Abstract][Full Text] [Related]
32. Olaparib (Lynparza) for advanced ovarian cancer.
Med Lett Drugs Ther; 2016 Feb; 58(1489):e32-3. PubMed ID: 26938702
[No Abstract] [Full Text] [Related]
33. Olaparib maintenance monotherapy in platinum-sensitive, relapsed ovarian cancer without germline
Poveda AM; Davidson R; Blakeley C; Milner A
Future Oncol; 2019 Nov; 15(32):3651-3663. PubMed ID: 31553234
[TBL] [Abstract][Full Text] [Related]
34. Can somatic BRCA2 status solve a case of olaparib monotherapy resistance?
Pietragalla A; Minucci A; Marchetti C; Scambia G; Fagotti A
Int J Gynecol Cancer; 2019 Nov; 29(9):1440-1445. PubMed ID: 31537621
[No Abstract] [Full Text] [Related]
35. [A Case of Recurrent Breast Cancer with Improving Activities of Daily Living by Olaparib Treatment].
Nakagawa T; Oda G; Okamoto K; Ishikawa T; Wakana K; Oshima N
Gan To Kagaku Ryoho; 2021 Dec; 48(13):1556-1558. PubMed ID: 35046254
[TBL] [Abstract][Full Text] [Related]
36. Sharing real-world experiences to optimize the management of olaparib toxicities: a practical guidance from an Italian expert panel.
Lorusso D; Bologna A; Cecere SC; De Matteis E; Scandurra G; Zamagni C; Arcangeli V; Artioli F; Bella M; Blanco G; Cardalesi C; Casartelli C; De Vivo R; Di Napoli M; Gisone EB; Lauria R; Lissoni AA; Loizzi V; Maccaroni E; Mangili G; Marchetti C; Martella F; Naglieri E; Parolin V; Ricciardi G; Ronzino G; Salutari V; Scarfone G; Secondino S; Spagnoletti I; Tasca G; Tognon G; Guarneri V
Support Care Cancer; 2020 May; 28(5):2435-2442. PubMed ID: 32048043
[TBL] [Abstract][Full Text] [Related]
37. Olaparib in germline-mutated metastatic breast cancer: implications of the OlympiAD trial.
Armstrong AC; Clay V
Future Oncol; 2019 Jul; 15(20):2327-2335. PubMed ID: 31304797
[TBL] [Abstract][Full Text] [Related]
38. Administration of the Tablet Formulation of Olaparib in Patients with Ovarian Cancer: Practical Guidance and Expectations.
Moore KN; Birrer MJ
Oncologist; 2018 Jun; 23(6):697-703. PubMed ID: 29593098
[TBL] [Abstract][Full Text] [Related]
39. Phase 1 trial of olaparib and oral cyclophosphamide in BRCA breast cancer, recurrent BRCA ovarian cancer, non-BRCA triple-negative breast cancer, and non-BRCA ovarian cancer.
Lee CK; Scott C; Lindeman GJ; Hamilton A; Lieschke E; Gibbs E; Asher R; Badger H; Paterson R; Macnab L; Kwan EM; Francis PA; Boyle F; Friedlander M
Br J Cancer; 2019 Feb; 120(3):279-285. PubMed ID: 30655615
[TBL] [Abstract][Full Text] [Related]
40. Response of
Xie Y; Jiang Y; Yang XB; Wang AQ; Zheng YC; Wan XS; Sang XT; Wang K; Zhang DD; Xu JJ; Li FG; Zhao HT
World J Gastroenterol; 2016 Dec; 22(46):10254-10259. PubMed ID: 28028375
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
